1-4 of 4
O. Ottmann
Close
Sort by
Journal Articles

Dasatinib (SPRYCEL®) 140 mg Once Daily (QD) vs 70 mg Twice Daily (BID) in Patients (pts) with Advanced Phase Chonic Myeloid Leukemia (ABP-CML) or Ph(+) ALL Who Are Resistant or Intolerant to Imatinib (im): Results of the CA180-035 Study.

Hagop Kantarjian, O. Ottmann, R. Pasquini, Y.T. Goh, D.W. Kim, J. VanTornout, A. Damokosh, N. Shah
Journal: Blood
Blood (2006) 108 (11): 746.
https://doi.org/10.1182/blood.V108.11.746.746
Published: 2006
Journal Articles

Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia.

I. Jilani, H. Kantarjian, H. Faraji, M. Gorre, J. Cortes, O. Ottmann, K. Bhalla, S. O’Brien, F. Giles, M. Albitar
Journal: Blood
Blood (2005) 106 (11): 2006.
https://doi.org/10.1182/blood.V106.11.2006.2006
Published: 2005
Journal Articles

Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.

M. Gorre, H. Kantarjian, I. Jilani, J. Cortes, A. Salvado, P. Rae, L. Alland, M. Dugan, O. Ottmann, K. Bhalla, F. Giles, M. Albitar
Journal: Blood
Blood (2005) 106 (11): 2001.
https://doi.org/10.1182/blood.V106.11.2001.2001
Published: 2005
Journal Articles

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

Francis Giles, MD, H. Kantarjian, MD, B. Wassmann, J. Cortes, MD, S. O’Brien, MD, C. Tanaka, P. Rae, W. Mietlowski, A. Romano, L. Alland, M. Dugan, M. Albitar, MD, O. Ottmann
Journal: Blood
Blood (2004) 104 (11): 22.
https://doi.org/10.1182/blood.V104.11.22.22
Published: 2004